-
Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015
•
Shenzhen-based Innorna Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for its proprietary mRNA drug, IN015, developed for the treatment of progressive familial intrahepatic cholestasis (PFIC). Understanding PFIC and the Impact of IN015Progressive familial intrahepatic cholestasis (PFIC)…
-
Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China
•
Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical Products Administration (NMPA) to commence clinical trials for its proprietary IN001, a novel mRNA vaccine designed to combat herpes zoster. This marks a significant milestone for the company, as IN001 is the first mRNA-based herpes…
-
Macera Therapeutics and Innorna Co., Ltd Collaborate on CAR-M mRNA-LNP Technology
•
Macera Therapeutics, a company based in Nanjing specializing in the development of macrophage immunotherapies, has entered into a partnership with Shenzhen-based Innorna Co., Ltd, a platform company focused on delivery platforms for nucleic acid therapeutics. Under the agreement, Macera will leverage Innorna’s mRNA-LNP technology to advance the development of in…
